These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35054088)

  • 1. Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection.
    Zarębska-Michaluk D; Jaroszewicz J; Parfieniuk-Kowerda A; Pawłowska M; Janczewska E; Berak H; Janocha-Litwin J; Klapaczyński J; Tomasiewicz K; Piekarska A; Krygier R; Citko J; Tronina O; Dobrowolska K; Flisiak R
    J Clin Med; 2022 Jan; 11(2):. PubMed ID: 35054088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea.
    Lim DH; Jeong JY; Nam S; Choi J; Kwon HC; Yoon YB; Kim Y; Chin B
    J Korean Med Sci; 2021 Nov; 36(46):e308. PubMed ID: 34845874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life effectiveness of antiviral therapy for HCV infection with pangenotypic regimens in HIV coinfected patients.
    Piekarska A; Berkan-Kawińska A; Berak H; Mazur W; Sitko M; Parfieniuk-Kowerda A; Lorenc B; Dybowska D; Janczewska E; Janocha-Litwin J; Dobracka B; Socha Ł; Tudrujek-Zdunek M; Flisiak R
    Expert Rev Anti Infect Ther; 2024 Sep; 22(9):775-780. PubMed ID: 38722307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting.
    Gayam V; Hossain MR; Khalid M; Chakaraborty S; Mukhtar O; Dahal S; Mandal AK; Gill A; Garlapati P; Ramakrishnaiah S; Mowyad K; Sherigar J; Mansour M; Mohanty S
    Gut Liver; 2018 Nov; 12(6):694-703. PubMed ID: 29938459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
    Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
    BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current guidelines and prioritizing treatment of hepatitis C virus in HIV-infected patients.
    Feeney ER; Chung RT; Yazdanpanah Y
    Curr Opin HIV AIDS; 2015 Sep; 10(5):323-9. PubMed ID: 26248119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic HCV genotype 1 coinfection.
    Boesecke C; Rockstroh JK
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
    Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
    HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
    Neukam K; Morano-Amado LE; Rivero-Juárez A; Mancebo M; Granados R; Téllez F; Collado A; Ríos MJ; de Los Santos-Gil I; Reus-Bañuls S; Vera-Méndez F; Geijo-Martínez P; Montero-Alonso M; Suárez-Santamaría M; Pineda JA
    HIV Clin Trials; 2017 May; 18(3):126-134. PubMed ID: 28599618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
    Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
    J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection.
    Montes ML; Olveira A; Ahumada A; Aldámiz T; García-Samaniego J; Clemente A; Berenguer J; González-García J; Martín-Carbonero L;
    AIDS; 2017 Jun; 31(9):1253-1260. PubMed ID: 28358742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics.
    Zarębska-Michaluk D; Jaroszewicz J; Parfieniuk-Kowerda A; Janczewska E; Dybowska D; Pawłowska M; Halota W; Mazur W; Lorenc B; Janocha-Litwin J; Simon K; Piekarska A; Berak H; Klapaczyński J; Stępień P; Sobala-Szczygieł B; Citko J; Socha Ł; Tudrujek-Zdunek M; Tomasiewicz K; Sitko M; Dobracka B; Krygier R; Białkowska-Warzecha J; Laurans Ł; Flisiak R
    J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pangenotypic triple
    Flisiak R; Zarębska-Michaluk D; Berak H; Dybowska D; Sitko M; Parfieniuk-Kowerda A; Janocha-Litwin J; Janczewska E; Piekarska A; Lorenc B; Mazur W; Dobrowolska K; Tudrujek-Zdunek M; Klapaczyński J; Jaroszewicz J
    Clin Exp Hepatol; 2023 Sep; 9(3):193-201. PubMed ID: 37790681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
    Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
    Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.
    Dietz J; Graf C; Berg CP; Port K; Deterding K; Buggisch P; Peiffer KH; Vermehren J; Dultz G; Geier A; Reiter FP; Bruns T; Schattenberg JM; Durmashkina E; Gustot T; Moreno C; Trauth J; Discher T; Fischer J; Berg T; Kremer AE; Müllhaupt B; Zeuzem S; Sarrazin C;
    JHEP Rep; 2024 Jul; 6(7):101072. PubMed ID: 39006503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection.
    Malin JJ; Boesecke C; Schwarze-Zander C; Wasmuth JC; Schlabe S; Trebicka J; Spengler U; Llibre JM; Jou T; Vasylyev M; Clotet B; Rockstroh JK
    HIV Med; 2019 Mar; 20(3):230-236. PubMed ID: 30687989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Clin Trials; 2018 Dec; 19(6):225-234. PubMed ID: 30890063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort.
    Quaranta MG; Ferrigno L; Monti M; Filomia R; Biliotti E; Iannone A; Migliorino G; Coco B; Morisco F; Vinci M; D'Ambrosio R; Chemello L; Massari M; Ieluzzi D; Russo FP; Blanc P; Verucchi G; Puoti M; Rumi MG; Barbaro F; Santantonio TA; Federico A; Chessa L; Gentile I; Zuin M; Parruti G; Morsica G; Kondili LA;
    Hepatol Int; 2020 May; 14(3):362-372. PubMed ID: 32279177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks.
    Corma-Gómez A; Macías J; Merino Muñoz D; Téllez F; Granados R; Morano LE; De Los Santos Gil I; Vera-Méndez FJ; Collado A; Palacios R; Pineda JA
    J Infect; 2019 Jul; 79(1):30-35. PubMed ID: 31100364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.